Adlai Nortye Group (ANL) vs Collegium Pharmaceutical (COLL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 572.6% versus a loss of 31.7%. Collegium Pharmaceutical is the larger company by market cap ($755.0 million vs $710.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | COLL |
|---|---|---|
| Share price | $11.03 | $23.19 |
| Market cap | $710.31M | $754.96M |
| 1-day change | -8.77% | +0.04% |
| YTD return | +676.76% | -49.91% |
| 1-year return | +572.56% | -31.67% |
| 5-year return | — | +10.11% |
| P/E ratio (TTM) | — | 18.26 |
| Forward P/E | — | 3.20 |
| EPS (TTM) | $-0.66 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $780.57M |
| Revenue growth (YoY) | — | +23.62% |
| Net income (latest FY) | $-51.87M | $62.87M |
| Gross margin | — | 59.35% |
| Operating margin | — | 23.01% |
| Net margin | — | 8.05% |
| 52-week high | $17.25 | $50.79 |
| 52-week low | $0.879 | $21.43 |
| Distance from 52-week high | -36.06% | -54.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +167.45% | +111.30% |
| Average volume | 212.90K | 777.33K |
| Shares outstanding | 58.73M | 32.56M |
| Employees | 109 | 423 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed COLL by 604.2 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
ANL vs COLL FAQ
Which is bigger, Adlai Nortye Group or Collegium Pharmaceutical?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $754.96M compared with $710.31M for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or COLL?
ANL returned +572.56% over the past 12 months, compared with -31.67% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Collegium Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.